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Patients with acute myeloid leukaemia show elevated plasma iron and, in 2/6 cases tudied, low-molecular-mass iron
complexes capable of stimulating radical reactions were present inthe plasma. Shortly after the onset of chemotherapy, 
there is a sharp rise in transferrin saturation and all patients studied showed low-molecular-mass ironin their plasma. 
It is proposed that such iron could interact with oxidants generated bycertain drugs (e.g. adriamycin ordaunorubicin) 
to facilitate tissue damage, and that some of the side-effects of chemotherapy might be ameliorated bycareful co-adminis- 
tration of small doses of desferrioxamine. 
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1. INTRODUCTION 
Hypoferraemia is a common finding in cancer 
patients [1], but acute leukaemia ppears to be an 
exception. Thus of 34 patients with acute myeloid 
leukaemia, 21 had high levels of serum iron and in 
17 the transferrin was reported to be iron-saturated 
[2]. Of 6 patients with acute lymphoblastic 
leukaemia, two had high levels of serum iron and 
fully saturated transferrin [2]. Similar results have 
been reported by others [3], and it is well establish- 
ed [4] that serum ferritin is elevated in acute 
leukaemia. 
The high percentage saturation of transferrin in 
patients with acute leukaemia raises the possibility 
that non-transferrin-bound, low-molecular-mass, 
serum iron complexes might be present in this 
disease. Such iron complexes can mediate tissue 
damage in several disease states by catalyzing free 
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radical reactions uch as the peroxidation of mem- 
brane lipids and the formation of highly reactive 
hydroxyl radical ('OH) from superoxide (O£) and 
hydrogen peroxide (HaOz) [5-7]. This is especially 
relevant because several of the drugs used to treat 
leukaemia, such as daunorubicin and adriamycin, 
lead to increased generation of O£ and H202 in 
vivo [8]. Indeed, an iron(III)-adriamycin complex 
('quelamycin') has proved to be much more toxic 
to humans than adriamycin itself [8,9]. 
Low-molecular-mass iron complexes, capable of 
stimulating free radical reactions, can be measured 
by a technique known as the bleomycin assay 
[6,10,11]. Bleomycin is an anti-tumour antibiotic 
that binds weakly to iron ions, and the bleomycin- 
iron complex degrades DNA in the presence of 
ascorbic acid as a reducing agent [10]. If 
bleomycin, ascorbate and DNA are in excess, the 
amount of DNA degradation is proportional to the 
concentration of iron ions available to bleomycin 
[11]. When applied to human serum samples, the 
bleomycin assay does not measure iron bound to 
ferritin or transferrin [6,11,12], but only low- 
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molecular-mass iron ions in forms that can 
stimulate free radical reactions. The bleomycin 
assay has been used in studies of iron overload 
disease [6,11,12], rheumatoid arthritis [7,10,11], 
and in several other disorders [10]. In the present 
paper, we have applied the assay to study such 
catalytic iron complexes in the serum of patients 
with acute leukaemia, before and during 
chemotherapy. 
2. MATERIALS AND METHODS 
Blood samples were taken, with informed consent, from the 
antecubital veins of patients with acute or chronic leukaemia 
immediately before, and at intervals during chemotherapy 
(described in the legend to table 2). Blood was allowed to clot 
and the serum was immediately subjected to the bleomycin 
assay [6]. Determinations of transferrin iron saturation and 
total serum iron were as described in [13]. Diagnoses were made 
by an experienced haematologist (G.M.). 
3. RESULTS 
Initial studies on 6 patients with acute myeloid 
leukaemia showed that plasma iron concentrations 
and percentage saturations of transferrin with iron 
tended to be greater than normal, in agreement 
with previous results [2,3]. Four of these patients 
showed no bleomycin-detectable iron in their 
plasma. However, in two patients (B and F) such 
iron was present despite the fact that transferrin 
was not completely saturated with iron. 
Bleomycin-detectable iron is never observed in 
plasma from healthy human subjects [6,10,11]. As 
a further control, plasma samples were obtained 
from 14 patients with chronic myelogenous 
leukaemia, who do not show elevations in plasma 
iron [1]. None of them showed any bleomycin- 
detectable iron. 
For four patients, further blood samples were 
obtained after chemotherapy had begun. Table 2 
shows that, in all cases, chemotherapy caused a 
rise in percentage transferrin saturation. 
Bleomycin-detectable iron appeared in the plasma 
in patients A and E, and its concentration rose in 
patients B and F. In patient E, both percentage 
transferrin saturation and concentrations of 
bleomycin-detectable iron were beginning to fall 
by 48 h after onset of chemotherapy. 
4. DISCUSSION 
Many cytotoxic drugs used in cancer 
chemotherapy generate oxidants such as superox- 
ide and H202, and these oxidants have been im- 
plicated in the side-effects produced by such drugs, 
e.g. the cardiotoxicity of anthracyclines [8]. Iron 
ions stimulate generation of highly-reactive ox- 
idants and they contribute to tissue injury in 
several diseases by this mechanism [5,10]. The 
bleomycin assay, when applied to plasma or 
serum, appears to measure iron ions capable of 
stimulating radical reactions [5-7,10-12]. Normal 
control subjects never show bleomycin-detectable 
iron; most plasma iron in healthy subjects is bound 
to the protein transferrin, and transferrin-bound 
iron will not stimulate radical reactions [5,14]. 
None of the patients with chronic lymphocytic 
leukaemia showed any bleomycin-detectable iron, 
nor did four of the patients with acute myeloid 
leukaemia (table 1). However, two of the latter pa- 
tients did show the presence of such iron, even 
though their plasma transferrin was not saturated. 
The existence of bleomycin-detectable iron concur- 
rent with incomplete transferrin saturation has 
also been reported in some patients with iron 
overload consequent upon idiopathic haemo- 
chromatosis [12,13] and possible reasons for this 
are discussed in [13]. 
The onset of chemotherapy presumably induces 
a massive destruction of leukaemic ells. Cytolysis 
would be expected to release internal iron pools 
from within cells [5]. The results in table 2 show 
that this effect was striking enough for there to be 
marked rises in the percentage saturation of 
transferrin and for bleomycin-detectable iron to 
appear in the plasma. The internal cellular iron 
pool of cells is thought o exist in a form that can 
stimulate free radical reactions [5,15]. Presumably 
some of the released iron binds to transferrin 
whilst the rest remains in a low-molecular-mass 
form, detectable in the bleomycin assay. 
Cell proliferation requires a source of iron, and 
there have been several suggestions that strong iron 
chelators uch as desferrioxamine could be used to 
halt rapid growth of leukaemia cells in vivo [16], as 
they do in vitro [17]. However, it would be dif- 
ficult to combine this cytostatic agent [15] with 
cytocidal agents such as adriamycin or 
daunorubicin which act on replicating cells [8]. 
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Table 1 
Plasma iron parameters in patients with acute myeloid 
leukaemia 
Patient Plasma iron 07o transferrin Bleomycin- 
code (,umol/dm 3) saturation detectable 
iron 
(umol/dm 3) 
A 35.0 73 0 
B 23.4 45 1.5 
C 22.7 58 0 
D 19.5 41 0 
E 21.4 50 0 
F 32.1 66 4.5 
Plasma iron normal values 17.9 _+ 6.7 #mol/dm 3,% transferrin 
saturation 29.9 +_ 10.2°70 
[15]). It is thus  poss ib le  that  smal l  doses  o f  desfer -  
r ioxamine ,  su f f i c ient  on ly  to  b ind  the b leomyc in -  
detectab le  i ron ,  might  d imin ish  the  radica l -  
med ia ted  in ju r ious  s ide-ef fects  o f  some drugs  used 
in cancer  chemotherapy  (e.g. daunorub ic in  or  
adr iamyc in )  w i thout  a f fec t ing  the i r  ac t ion  aga ins t  
leukaemic  cells. 
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